Erin Mistry
Corporate Officer/Principal presso CORMEDIX INC.
Patrimonio netto: 55 167 $ in data 31/03/2024
Profilo
Erin Mistry is currently the Chief Commercial Officer & Senior Vice President at CorMedix, Inc. (since 2023).
Prior to this, Mr. Mistry worked as the Vice President - Market Access at Intarcia Therapeutics, Inc.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CORMEDIX INC.
0.02% | 07/03/2024 | 13 011 ( 0.02% ) | 55 167 $ | 31/03/2024 |
Posizioni attive di Erin Mistry
| Società | Posizione | Inizio |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | 01/01/2020 |
Precedenti posizioni note di Erin Mistry
| Società | Posizione | Fine |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Erin Mistry
